Isovolumetric Multimodal Venous Thrombectomy System
等容多模式静脉取栓系统
基本信息
- 批准号:10323857
- 负责人:
- 金额:$ 98.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgitationAmericanAnimalsAnticoagulationBalloon OcclusionBiomedical EngineeringBiomedical ResearchBlood VesselsBlood coagulationCaliberCathetersCessation of lifeChemicalsChronicClinicalClinical TrialsCoagulation ProcessCollaborationsComplicationDeep Vein ThrombosisDevelopmentDevice DesignsDevicesDiagnosisDistalElementsEmbolismEngineeringEntrepreneurshipExcisionFamily suidaeFeasibility StudiesFlushingFreezingGenerationsGoalsHealthHealthcare SystemsHemorrhageHospitalsImpairmentIncidenceIndividualInfusion PumpsInfusion proceduresInternationalKnowledgeLeadLettersLiquid substanceLungMarketingMechanicsMedical DeviceMethodsModalityModelingMorbidity - disease rateNeurosurgeonOutcomePatientsPerioperativePharmaceutical PreparationsPhaseProceduresPublic HealthPumpQuality of lifeReportingResearch PersonnelResidual stateRiskSafetySavingsSmall Business Technology Transfer ResearchSuctionSurgeonSystemTechniquesTechnologyTestingTherapeuticTherapeutic EmbolizationThrombectomyThrombosisThrombusTraumaTreatment CostTreatment EfficacyUnited States Food and Drug AdministrationUniversitiesVacuumVeinsVena Cava OcclusionVena caval structureVenousVeterinariansWashingtoncommercial applicationcomparativecost effectivedesignendovascular thrombectomyexperiencegood laboratory practiceimprovedin vivoin vivo evaluationinnovationinterestmedical schoolsmortalitymortality riskmultimodalitynovelphase 1 studyphase 2 studypressurepreventprocedure costprototyperestorationsynergismtechnological innovationthrombolysis
项目摘要
ABSTRACT
This Phase II STTR application from Caeli Vascular, LLC entails a 24-month period focused on further
development of a novel multi-modal venous thrombectomy device. The PI is a vascular surgeon with
biomedical research and entrepreneurship experience, and is supported by a team of highly qualified
investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, mechanical
engineer, and a team of marketing and management experts. The primary objective of this application is to
build on successful Phase I feasibility studies, and further develop the Hydra Catheter Thrombectomy System
technology to address all current gaps in the state of the art for the treatment of large-volume deep venous
thrombus (DVT).
Each year, more than 900,000 Americans will develop a large-volume DVT, and up to 100,000 of these will
die as a result of a complication within 2 weeks of diagnosis. Treatment options of large-volume DVT are
limited, and currently available percutaneous endovascular thrombectomy devices have various shortcomings
that impact treatment efficacy and safety. Major gaps include increased risk of intra-procedural thrombus
embolization leading to a pulmonary embolus (PE), systemic leak of chemical thrombolytic medication leading
to increased risk of bleeding, risk of vein wall and valve trauma leading to chronic impairments, and inability to
completely remove thrombus leading to unresolved DVT. To address all the gaps in the state of the art of
percutaneous venous thrombectomy devices we designed and prototyped the Hydra Catheter Thrombectomy
System. Unique and proprietary features of the device include adjustable ecapsulation balloons, an infusion
catheter segment to facilitate localized and judicious delivery of chemical thrombolytics, a rail-mounted leaflet
agitator that does not engage the vein wall, and mechanism for isovolumetric suction and infusion to facilitate
flushing of thrombus fragments and thrombolytics from the venous treatment zone. Phase I studies
demonstrated the feasibility of the device to prevent distal microembolization, prevent vein wall collapse and
over-distension, and achieve effective removal of luminal thrombus in an ex vivo flow system. In this Phase II
study, our team will further develop key component of the device and evaluate the efficiency of the technology
ex vivo and in vivo with the following specific aims:
Aim 1: Develop and test a newer generation Hydra Pump to facilitate isovolumetric suction and infusion
through the Hydra Catheter Thrombectomy System in an ex vivo flow system.
Aim 2: Evaluate Hydra Catheter Thrombectomy System efficacy and preliminary safety in a validated in
vivo porcine vena cava DVT model
By completing these proposed aims we will be able to achieve the design specifications and Good
Laboratory Practice (GLP) animal studies that are required for FDA 510(k) device application submission.
抽象的
Caeli Vascular, LLC 的第二阶段 STTR 申请需要 24 个月的时间,重点关注进一步
开发新型多模式静脉血栓切除装置。 PI 是一名血管外科医生
生物医学研究和创业经验,并有高素质团队支持
研究人员,包括血管生物学家、神经外科医生、兽医、生物医学工程师、机械工程师
工程师,以及营销和管理专家团队。该应用程序的主要目标是
以成功的一期可行性研究为基础,进一步开发 Hydra 导管血栓切除系统
技术可解决目前治疗大容量深静脉的所有现有技术差距
血栓(DVT)。
每年,超过 900,000 名美国人将出现大量 DVT,其中多达 100,000 名美国人将患上深静脉血栓 (DVT)。
诊断后 2 周内因并发症死亡。大容量 DVT 的治疗选择是
有限,目前可用的经皮血管内取栓装置存在各种缺点
影响治疗效果和安全性。主要差距包括术中血栓风险增加
栓塞导致肺栓塞(PE),化学溶栓药物的全身泄漏导致
出血风险增加、静脉壁和瓣膜损伤导致慢性损伤的风险以及无法
彻底清除导致未解决的 DVT 的血栓。解决现有技术中的所有差距
我们设计并制作了 Hydra 导管血栓切除术原型的经皮静脉血栓切除术设备
系统。该设备的独特和专有功能包括可调节的封装球囊、输液
导管段,以促进化学溶栓剂的局部和明智的输送,轨道安装的传单
不接触静脉壁的搅拌器,以及等容抽吸和输注机制,以促进
从静脉治疗区冲洗血栓碎片和溶栓剂。第一阶段研究
证明了该装置防止远端微栓塞、防止静脉壁塌陷和
过度扩张,并在离体流动系统中实现管腔血栓的有效清除。在本次第二阶段
研究中,我们的团队将进一步开发该设备的关键部件并评估该技术的效率
离体和体内的具体目标如下:
目标 1:开发并测试新一代 Hydra 泵,以促进等容抽吸和输注
通过离体流动系统中的 Hydra 导管血栓切除系统。
目标 2:评估 Hydra 导管血栓切除系统的有效性和初步安全性
活体猪腔静脉DVT模型
通过完成这些提出的目标,我们将能够实现设计规范和良好的目标
提交 FDA 510(k) 设备申请所需的实验室实践 (GLP) 动物研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stacey Liekweg其他文献
Stacey Liekweg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stacey Liekweg', 18)}}的其他基金
Isovolumetric Multimodal Venous Thrombectomy System
等容多模式静脉取栓系统
- 批准号:
10458775 - 财政年份:2020
- 资助金额:
$ 98.1万 - 项目类别:
相似海外基金
Relationship between Biomarkers of Oxidative Stress and Agitation Severity in Moderate-to-severe Alzheimer's Disease
中重度阿尔茨海默病氧化应激生物标志物与躁动严重程度之间的关系
- 批准号:
497994 - 财政年份:2023
- 资助金额:
$ 98.1万 - 项目类别:
Effects of dexmedetomidine on agitation in critically ill TBI patients - DEX-TBI
右美托咪定对危重 TBI 患者躁动的影响 - DEX-TBI
- 批准号:
488402 - 财政年份:2023
- 资助金额:
$ 98.1万 - 项目类别:
Operating Grants
Co-design and evaluation of sensor-instrumented ‘smart socks’ (MPATIX) to improve management of distress and agitation for people with dementia
共同设计和评估传感器仪表“智能袜子”(MPATIX),以改善痴呆症患者的痛苦和躁动管理
- 批准号:
10055596 - 财政年份:2023
- 资助金额:
$ 98.1万 - 项目类别:
Collaborative R&D
Identifying pre-agitation biometric signature in dementia patients: A feasibility study
识别痴呆症患者的躁动前生物识别特征:可行性研究
- 批准号:
486612 - 财政年份:2022
- 资助金额:
$ 98.1万 - 项目类别:
Studentship Programs
Relationship between 4-Hydroxynonenal and Agitation Severity in Alzheimer’s Disease
4-羟基壬烯醛与阿尔茨海默病患者躁动严重程度之间的关系
- 批准号:
486589 - 财政年份:2022
- 资助金额:
$ 98.1万 - 项目类别:
Studentship Programs
Agitation in Alzheimer's Disease: Identification and Prediction Using Digital Behavioral Markers and Indoor Environmental Factors
阿尔茨海默病中的躁动:使用数字行为标记和室内环境因素进行识别和预测
- 批准号:
10404523 - 财政年份:2021
- 资助金额:
$ 98.1万 - 项目类别:
Clinical Decision Support Tool to Assess Risk and Prevent Agitation Events
用于评估风险和预防躁动事件的临床决策支持工具
- 批准号:
10683499 - 财政年份:2021
- 资助金额:
$ 98.1万 - 项目类别:
Development of Memesto, a wearable repetitive message and music therapy device that senses and reduces agitation in persons with AD/ADRD.
开发 Memesto,一种可穿戴式重复信息和音乐治疗设备,可感知并减少 AD/ADRD 患者的躁动。
- 批准号:
10322846 - 财政年份:2021
- 资助金额:
$ 98.1万 - 项目类别:
Agitation in Alzheimer's Disease: Identification and Prediction Using Digital Behavioral Markers and Indoor Environmental Factors
阿尔茨海默病中的躁动:使用数字行为标记和室内环境因素进行识别和预测
- 批准号:
10190522 - 财政年份:2021
- 资助金额:
$ 98.1万 - 项目类别:
Clinical Decision Support Tool to Assess Risk and Prevent Agitation Events
用于评估风险和预防躁动事件的临床决策支持工具
- 批准号:
10365272 - 财政年份:2021
- 资助金额:
$ 98.1万 - 项目类别: